胱氨酸蛋白酶抑制剂C预示CABG术后患者中期心血管事件风险的应用研究
被引量：2
摘要
胱氨酸蛋白酶抑制剂C（CystatinC）是一种内源性胱氨酸蛋白酶抑制剂，相对分子质量为13000，较低，它由有核细胞以相对比较稳定的速度合成并释放到血浆中去。作为肾功能的标志物，CystatinC与Scr相比有很多的优势，它的分泌不受年龄、性别、身高、体重、肌肉量等因素的影响。
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2011年第9期790-792,共3页
Chinese Journal of Laboratory Medicine
参考文献14
-
1World Health Organization.Global Tuberculosis Control a short update to the 2009 report.2010.
-
2Dharnidharka VR, Kwon C, Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis, 2002, 40:221-226.
-
3Filler G, Bokenkamp A, Hofmann W, et al. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem, 2005, 38 : 1-8.
-
4Mussap M, Dalla Vestra M, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int, 2002, 61:1453-1461.
-
5Koenig W, Twardella D, Brenner H, et al. Plasma concentrations of Cystatin C in patients with coronary heart disease and risk for secondary ardiovascular events: more than simply a marker of glomerular filtration rate. Ctin Chem, 2005, 51:321-327.
-
6Muntner P, Mann D, Winston J, et al. Serum Cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol, 2008, 102:54-57.
-
7Ix JH, Shlipak MG, Chertow GM, et al. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail, 2006, 12:601-607.
-
8Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med, 2005, 352:2049-2060.
-
9Fried LF, Katz R, Sarnak MJ, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol, 2005, 16:3728-3735.
-
10Drey N, Roderick P, Mullee M, et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis, 2003, 42:677-684.
同被引文献25
-
1Momiyama Y,0hmori R,Fayad ZA,et a1.Associations between serum lipopmtein(a)levels and the severity of coronary and aortic athemsclemsis[J].At Ilemsclerosis,2012,222(1):241-244.
-
2Goldstein LB,Bushnell CD,Adams RJ,et al.Guidelines for the primary prevention of stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2011,42(2):517-584.
-
3Stem JM,Saver JL,Boldy RM.Homocysteine associated hypercoagulability and disseminated thrombosis a care report[J].Angiology,1998,49:765-769.
-
4Iwamoto T,Fukuda S,Shimizu S,et a LLong-tem effects of Lipoprotein(a)on carotid atheresclerosis in elderly Japanese[J].J Gerontel A Biol Sci Med Sci,2004,59(1):62-67.
-
5Gazzaruso C,Bruno R,Pujia A,et a1.Lipoprotein(a),apolipoprotein(a)polymorphism and coronary atheroscleresis severity in type 2 dia_betic patients[J].Int J Cardiol,2006,108(3):354-358.
-
6Akhabue E,Thiboutot J,Cheng JW,et a1.New and emerging risk factors for coronary heart disease[J].Am J Med Sci,2014,347:151-158.
-
7姚雯颖,胡琼.胱抑素C与尿微量白蛋白／肌酐诊断糖尿病早期肾损伤的临床价值[J].中国基层医药,2009,16(10):1824-1824. 被引量：9
-
8李军辉,邢涛,汪年松.急性肾损伤与妊娠关系的研究进展[J].中国中西医结合肾病杂志,2011,12(7):654-656. 被引量：8
-
9钟琳玲,廖芳.血清同型半胱氨酸与冠心病的相关性研究[J].实用心脑肺血管病杂志,2011,19(10):1713-1713. 被引量：20
-
10陈学军,沈月芳,钟小薇,周晨,徐辉,程永樟.儿童透射比浊法血清半胱氨酸蛋白酶抑制剂C参考区间的建立及其与年龄、性别的相关性[J].中华检验医学杂志,2011,34(9):785-790. 被引量：7
-
1王家驷,舒仁明,王廷杰,周培健.脑脊液CystatinC在判断脑实质损伤中的价值探讨[J].现代检验医学杂志,2010,25(2):87-89. 被引量：3
-
2任应鹏,赵肖丽,刘东红,叶雅丽,陈自力.心房颤动患者幽门螺杆菌感染与胱氨酸蛋白酶抑制剂C、血脂的关系[J].全科医学临床与教育,2013,11(1):27-29. 被引量：4
-
3屠强,彭启松.血胱氨酸蛋白酶抑制剂C与同型半胱氨酸联合检测对2型糖尿病肾病诊断的应用价值探讨[J].中国实用医药,2013,8(29):58-59. 被引量：4
-
4李琴春,孟立辉,马金珠.胱氨酸蛋白酶抑制剂C对糖尿病患者肾小球损伤的早期诊断[J].中国医学创新,2013,10(6):94-95. 被引量：2
-
5劳小平,简祟东,叶长广.血清hs-CRP同型半胱氨酸及胱氨酸蛋白酶抑制剂C水平检测在急性脑梗死患者中临床价值[J].河北医学,2015,21(2):195-198. 被引量：1
-
6改变基因使人更强壮[J].百科知识,2004(9):32-32.
-
7向洪洲,任为.组织蛋白酶B及其抑制剂Cystatin C在人腹主动脉瘤平滑肌细胞中的表达[J].中国动脉硬化杂志,2010,18(6):350-352. 被引量：2
-
8林泉,黄怃,董清秀,钱红姣.重症肺炎患儿血清胱氨酸蛋白酶抑制剂C测定分析[J].福建医药杂志,2014,36(5):175-175.
-
9陈娴,林越仙,夏克惜.小儿重症肺炎42例尿微量白蛋白和血胱氨酸蛋白酶抑制剂C等检测结果分析[J].中国乡村医药,2011,18(8):61-62.
-
10尤玲,赵春霞,邵娇梅,张珞,汪道文.非对称性二甲基精氨酸和胱氨酸蛋白酶抑制剂C与冠心病[J].中华心血管病杂志,2010,38(9):798-800.
